Latest news with #Paxil
New York Post
4 days ago
- Health
- New York Post
Warning to antidepressant users as heat wave temperatures hit 100 degrees
Can't take the heat? Your medication might be to blame. Doctors are warning that people taking certain antidepressants could be at risk of serious health problems as temperatures soar into the triple digits. They're urging users to take extra precautions as the tri-state swelters — before it's too late. Advertisement 3 Dr. Zachary Rubin is warning antidepressant users to be extra careful in the heat. TikTok/@rubin_allergy 'If you're taking certain antidepressants, you may be at risk for developing heat intolerance and dehydration,' Dr. Zachary Rubin, a pediatrician and immunologist, warned in a recent TikTok video. Studies show about 1 in 8 American adults take antidepressants. Research suggests that two major types can interfere with how the body regulates temperature. The first group, selective serotonin reuptake inhibitors (SSRIs), includes widely prescribed drugs like Prozac (fluoxetine), Zoloft (sertraline), Lexapro (escitalopram), Paxil (paroxetine) and Celexa (citalopram). Advertisement The second group, tricyclic antidepressants (TCAs), includes older meds such as Elavil (amitriptyline), Anafranil (clomipramine) and Silenor (doxepin). Studies show these medications can spike internal body temps to 106°F or higher — while also throwing a wrench in the body's natural cooling system. 'You may excessively sweat or you may not be able to sweat quite as much,' Rubin explained. Advertisement 3 Sweat helps protect the body from overheating. Getty Images That's no small issue: Sweating is the body's primary defense against overheating. Without it, your chances of heatstroke, organ failure and even death increases substantially. Research shows SSRIs and TCAs may also mess with the hypothalamus, a part of the brain that helps regulate body temperature, thirst and blood pressure. Advertisement 'When the hypothalamus cannot control body temperature, someone can overheat,' Dr. David Tzall, a licensed psychologist, told Medical News Today. That increased heat sensitivity increases your chances of heat exhaustion, which has symptoms such as dizziness, nausea, muscle cramps, headaches and heavy sweating, according to the Cleveland Clinic. Left unchecked, heat exhaustion can quickly escalate into heat stroke — the most dangerous form of heat-related illness. At that stage, the body can begin to shut down, triggering seizures, hot dry skin or intense sweating, loss of consciousness and serious brain trouble, including confusion, erratic behavior and slurred speech. In extreme cases, heat stroke can cause permanent disability or death. 'If you begin to feel a rapid heartbeat, start sweating excessively, develop nausea, dizziness or leg cramping, immediately seek air conditioning and if necessary, have someone call 911,' Dr. Robert Glatter, an emergency medicine physician, told Still, experts say SSRIs and TCAs are safe and effective — as long as patients know the risks and can spot the warning signs before things turn dangerous. Advertisement 3 SSRIs are the most popular form of antidepressants on the market. nenetus – Rubin recommends staying hydrated, avoiding direct sun and wearing loose, light-colored clothing when temperatures climb. 'If you are struggling at all, make sure that you seek out help,' he said. The warnings come as a once-in-a-century scorcher grips the East Coast, with more than 150 million Americans currently living under 'extreme' heat alerts. Advertisement Each summer, more than 500 New Yorkers die prematurely because of hot weather, a figure that has been climbing in recent years. 'This week's heat wave could be deadly and life threatening if you are not prepared,' Mayor Eric Adams warned in a recent public safety alert.
Yahoo
02-05-2025
- Health
- Yahoo
PTSD market expected to reach $5.5bn across the 7MM by 2034
The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from $1.2bn in 2024 to $5.5bn by 2034 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Australia), according to leading data and analytics company GlobalData's recent report, Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast. The major driving factors of this growth include an increase in prevalent cases, the entry of eight novel late-stage pipeline products that are all anticipated to be significantly more expensive than the widely used generic drugs currently dominating the market, and an increasing awareness and reduced stigma surrounding PTSD in the general population, leading to higher rates of healthcare presentation and increased diagnosis and treatment rates. A major focus of research and development (R&D) in the PTSD therapeutic space is the development of new therapeutic options with improved efficacy. As no medications have been approved by the US Food and Drug Administration (FDA) for the treatment of PTSD since 2001, antidepressants of the selective-serotonin reuptake inhibitors (SSRIs) class, of which Zoloft and Paxil are the only approved drugs for PTSD, have been relied upon by physicians worldwide and the consensus is that this strategy is unsuitable for many patients. While SSRIs can result in symptom reduction for PTSD patients, less than 30% of patients achieve remission. The PTSD pipeline is diverse with novel mechanisms of action that developers hope can provide greater efficacy than the SSRIs. One significant area of research is into psychedelic therapeutics. Key opinion leaders (KOLs) interviewed by GlobalData consistently highlighted midomafetamine hydrochloride (MDMA) as the most promising psychedelic therapeutic for PTSD, with Lykos Therapeutics' MDMA-assisted psychotherapy expected to achieve blockbuster status by the end of the forecast period. Despite a challenging path towards the market, having been initially rejected by the FDA in August 2024 and KOLs noting some concerns surrounding trial design and company practice, as the first psychedelic to reach the market for PTSD, GlobalData forecasts Lykos' drug will generate $1.1 billion in sales across the 7MM by 2034. Despite their promise, many regulatory challenges exist for psychedelic therapeutics, particularly those that are being developed in conjunction with psychotherapy, including how to attribute benefits between the drug component and the psychotherapy component in a trial, especially as the FDA does not regulate psychotherapy. Furthermore, the known effects of psychedelics make double-blind placebo control, the gold standard for clinical trials, difficult to achieve, as patients can identify when they have received the active compound. This leads to concerns of expectation bias in participants, which can affect the evaluation of the true efficacy of a drug. The other psychedelic therapeutics in the late-stage PTSD pipeline are Compass Pathways' psilocybin and Seelos Therapeutics' ketamine. In addition to the three psychedelic therapeutics, there are five non-psychedelic pipeline products in the late-stage PTSD pipeline that GlobalData expects to launch during the forecast period (2024-2034). These are Otsuka's Rexulti, which is currently in preregistration in the US, Neuphoria Therapeutics' BNC-210, Idorsia Pharmaceuticals' Quviviq, Ananda Scientific's Nantheia ATL5, and Transcend Therapeutics' TSND-20. Many of these products have safety profiles favourable to the current treatment options, helping to meet another key unmet need in the PTSD market as the problem of side effects with existing treatments leads to low patient compliance rates. GlobalData expects that the five non-psychedelic pipeline products will generate $2.3bn in sales in the 7MM by 2034. "PTSD market expected to reach $5.5bn across the 7MM by 2034" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
